Combination Therapy in Cancers With Mutations in DNA Repair Genes NCT05694715 Metastatic Soli...
BRCA1 Mutation
BRCA2 Mutation
ATM Gene Mutati...
PALB2 Gene Muta...
Niraparib
Irinotecan
18 Years - University of California, San Francisco View Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes NCT02286687 Advanced Malign...
ATM Gene Mutati...
BRCA1 Gene Muta...
BRCA2 Gene Muta...
Metastatic Mali...
PALB2 Gene Muta...
Recurrent Malig...
Refractory Mali...
Laboratory Biom...
Pharmacological...
Talazoparib
18 Years - M.D. Anderson Cancer Center View Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion NCT06033092 BRCA Mutation
PALB2 Gene Muta...
Ductal Carcinom...
Lobular Carcino...
ATM Gene Mutati...
CHEK2 Gene Muta...
CDH1 Gene Mutat...
RAD51C Gene Mut...
RAD51D Gene Mut...
Tamoxifen 10 mg...
Intermittent ca...
Step counter De...
18 Years - 70 Years European Institute of Oncology View Combination of Olaparib and Navitoclax in Women With HGSC and TNBC NCT05358639 High Grade Sero...
Triple Negative...
Ovarian Cancer
Olaparib tablet
Navitoclax
18 Years - Sunnybrook Health Sciences Centre View Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion NCT06033092 BRCA Mutation
PALB2 Gene Muta...
Ductal Carcinom...
Lobular Carcino...
ATM Gene Mutati...
CHEK2 Gene Muta...
CDH1 Gene Mutat...
RAD51C Gene Mut...
RAD51D Gene Mut...
Tamoxifen 10 mg...
Intermittent ca...
Step counter De...
18 Years - 70 Years European Institute of Oncology View Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors NCT06177171 BRCA1 Mutation
BRCA2 Mutation
BRCA Mutation
PALB2 Gene Muta...
Checkpoint Kina...
ATM Gene Mutati...
Olaparib
ASTX727
18 Years - University of California, San Francisco View Combination of Olaparib and Navitoclax in Women With HGSC and TNBC NCT05358639 High Grade Sero...
Triple Negative...
Ovarian Cancer
Olaparib tablet
Navitoclax
18 Years - Sunnybrook Health Sciences Centre View Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer NCT03377556 ATM Gene Mutati...
ATR Gene Mutati...
BARD1 Gene Muta...
BRCA1 Gene Muta...
BRCA2 Gene Muta...
BRIP1 Gene Muta...
CHEK1 Gene Muta...
CHEK2 Gene Muta...
FANCA Gene Muta...
FANCC Gene Muta...
FANCD2 Gene Mut...
FANCF Gene Muta...
FANCM Gene Muta...
NBN Gene Mutati...
PALB2 Gene Muta...
RAD51 Gene Muta...
RAD51B Gene Mut...
RAD54L Gene Mut...
Recurrent Squam...
RPA1 Gene Mutat...
Stage IV Squamo...
Laboratory Biom...
Pharmacological...
Talazoparib
- SWOG Cancer Research Network View Talazoparib in Treating Patients With Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes NCT02286687 Advanced Malign...
ATM Gene Mutati...
BRCA1 Gene Muta...
BRCA2 Gene Muta...
Metastatic Mali...
PALB2 Gene Muta...
Recurrent Malig...
Refractory Mali...
Laboratory Biom...
Pharmacological...
Talazoparib
18 Years - M.D. Anderson Cancer Center View Olaparib In Metastatic Breast Cancer NCT03344965 Metastatic Brea...
Invasive Breast...
Somatic Mutatio...
Somatic Mutatio...
CHEK2 Gene Muta...
ATM Gene Mutati...
PALB2 Gene Muta...
RAD51 Gene Muta...
BRIP1 Gene Muta...
NBN Gene Mutati...
Olaparib
18 Years - Beth Israel Deaconess Medical Center View Combination of Olaparib and Navitoclax in Women With HGSC and TNBC NCT05358639 High Grade Sero...
Triple Negative...
Ovarian Cancer
Olaparib tablet
Navitoclax
18 Years - Sunnybrook Health Sciences Centre View